Ergomed plc Ergomed Notice of Preliminary Results (9439C)
28 Febrero 2022 - 01:01AM
UK Regulatory
TIDMERGO
RNS Number : 9439C
Ergomed plc
28 February 2022
PRESS RELEASE
Notice of Preliminary Results
Guildford, UK - 28 February 2022: Ergomed plc, (LSE: ERGO)
("Ergomed" or the "Company"), a company focused on providing
specialised services to the pharmaceutical industry, will announce
its preliminary results for the year ending 31 December 2021 on
Tuesday 29 March 2022.
Miroslav Reljanović, Executive Chairman, Richard Barfield, Chief
Financial Officer, and Keith Byrne, Senior Vice-President, Capital
Markets & Strategy, will host an in-person briefing for
analysts at 9.30am GMT on the day of the results at the offices of
Numis, 45 Gresham St, London EC2V 7BF. There will also be a live
webcast and conference call with a Q&A session.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402
975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital
Markets & Strategy)
Numis (Nominated Advisor and Joint Broker) Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated
Adviser)
James Black (Broker)
Peel Hunt LLP (Joint Broker) Tel: +44 (0) 20 7418
James Steel / Dr Christopher Golden 8900
Consilium Strategic Communications - for Tel: +44 (0) 20 3709 5700
UK enquiries
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
Angela Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing
services business includes an industry-leading suite of specialist
pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand and a full range of high-quality clinical
research and trial management services under the Ergomed brand
(CRO). For further information, visit: http://ergomedplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOREAEAXAAKAEAA
(END) Dow Jones Newswires
February 28, 2022 02:01 ET (07:01 GMT)
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024